These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 18538839)

  • 21. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
    Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
    Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
    Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
    Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
    Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
    Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
    Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
    Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes.
    Hauck G; Jonigk D; Göhring G; Kreipe H; Hussein K
    Cancer Genet; 2013 Apr; 206(4):116-23. PubMed ID: 23571153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives.
    Barosi G; Rosti V; Gale RP
    Leukemia; 2023 Apr; 37(4):725-727. PubMed ID: 36871061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.
    Tefferi A; Sirhan S; Sun Y; Lasho T; Finke CM; Weisberger J; Bale S; Compton J; LeDuc CA; Pardanani A; Thorland EC; Shevchenko Y; Grodman M; Chung WK
    Leuk Res; 2009 May; 33(5):662-4. PubMed ID: 18937974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia.
    Koopmans SM; Bot FJ; Lam KH; van Marion AM; de Raeve H; Hebeda KM
    Am J Clin Pathol; 2011 Oct; 136(4):618-24. PubMed ID: 21917685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How I Diagnose Primary Myelofibrosis.
    Prakash S; Orazi A
    Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
    Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
    Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J; Kvasnicka HM; Vardiman J
    Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
    Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
    PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
    Andrieux J; Roche-Lestienne C; Geffroy S; Desterke C; Grardel N; Plantier I; Selleslag D; Demory JL; Laï JL; Leleu X; Le Bousse-Kerdiles C; Vandenberghe P
    Cancer Genet Cytogenet; 2007 Oct; 178(1):11-6. PubMed ID: 17889703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.